Skip to main content
Erschienen in: Archives of Osteoporosis 1/2021

01.12.2021 | Original Article

Evaluation of care delivery by a novel multidisciplinary bone health clinic for patients at risk of glucocorticoid-induced osteoporosis

verfasst von: Hasan Abdullah, Greg Koller, Ines Zuna, Nese Yuksel, Theresa Charrois, Rashmi Mandhane, Kathy Cotton, Melanie Danilak, Holly Bell, Carrie Ye

Erschienen in: Archives of Osteoporosis | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Summary

Glucocorticoid-induced osteoporosis (GIOP) is a common condition associated with increased risk for fracture. Many patients receive suboptimal care. We created a novel GIOP clinic model which successfully fills a gap in osteoporosis care by providing multidisciplinary intervention in key components of GIOP preventive care to an underserved patient population.

Introduction

This study characterizes the patient population referred to our novel glucocorticoid-induced osteoporosis (GIOP) clinic and evaluates how well the clinic performed in addressing key components of GIOP preventive care.

Methods

This population-based prospective cohort study derives data from patients reviewed at the University of Alberta Multidisciplinary Bone Health Clinic from January 2017 to September 2019. To create our clinic model, key components of GIOP preventive care were summarized based on current guidelines, and clear responsibilities were delegated to each multidisciplinary team member. A REDCap database was constructed, and each patient’s multidisciplinary assessment was entered at each visit. Demographic and treatment data was extracted from our database.

Results

The clinic was able to achieve optimal GIOP preventive care in 60.1% of patients and in 78.7% of patients when excluding wait time. Of the 245 GIOP patients assessed, over half were females (56.7%) and the mean age was 56.7 years (range 16–95 years). Referrals were primarily made by specialists. Low-trauma fractures were reported in 24.9% of patients and 95.5% of patients had a baseline dual-energy X-ray absorptiometry (DXA). The mean current daily prednisone-equivalent dose was 14.1 mg. All patients received a recommendation for pharmacotherapy (100%) and the majority received counseling on vitamin D (98.8%), calcium (97.8%), smoking cessation (98.8%), alcohol reduction (98.4%), falls prevention (88.6%), and exercise (85.3%).

Conclusion

Our novel GIOP clinic model successfully fills a gap in osteoporosis care by providing multidisciplinary intervention in key components of GIOP preventive care to an underserved patient population. Further studies are required to assess the real-world long-term outcomes of our model.
Literatur
1.
Zurück zum Zitat NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785–795 NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785–795
2.
Zurück zum Zitat Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B et al (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96(2):115–123CrossRef Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B et al (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96(2):115–123CrossRef
3.
Zurück zum Zitat Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S et al (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39(2):253–259CrossRef Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S et al (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39(2):253–259CrossRef
4.
Zurück zum Zitat Laan RF, van Riel PL, van de Putte LB, van Erning LJ, Hof van’t MA, Lemmens JA (1993) Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 119(10):963–8CrossRef Laan RF, van Riel PL, van de Putte LB, van Erning LJ, Hof van’t MA, Lemmens JA (1993) Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 119(10):963–8CrossRef
5.
Zurück zum Zitat Amiche MA, Abtahi S, Driessen JHM, Vestergaard P, de Vries F, Cadarette SM et al (2018) Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. Arch Osteoporos 13(1):30CrossRef Amiche MA, Abtahi S, Driessen JHM, Vestergaard P, de Vries F, Cadarette SM et al (2018) Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. Arch Osteoporos 13(1):30CrossRef
6.
Zurück zum Zitat Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD et al (2016) Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int 27(5):1709–1718CrossRef Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD et al (2016) Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int 27(5):1709–1718CrossRef
7.
Zurück zum Zitat Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O’Malley CD et al (2016) Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int 27(11):3239–3249CrossRef Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O’Malley CD et al (2016) Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int 27(11):3239–3249CrossRef
8.
Zurück zum Zitat Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE et al (2017) 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 69(8):1521–37CrossRef Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE et al (2017) 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 69(8):1521–37CrossRef
9.
Zurück zum Zitat Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al (2010) clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010/10/12. 2010 Nov 23;182(17):1864–73. Available from: https://pubmed.ncbi.nlm.nih.gov/20940232 Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al (2010) clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010/10/12. 2010 Nov 23;182(17):1864–73. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​20940232
10.
Zurück zum Zitat Kanis JA, Cooper C, Rizzoli R, Reginster J-Y, (IOF) on behalf of the SAB of the ES for C and EA of O (ESCEO) and the C of SA and NS of the IOF (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3–44. https://doi.org/10.1007/s00198-018-4704-5CrossRef Kanis JA, Cooper C, Rizzoli R, Reginster J-Y, (IOF) on behalf of the SAB of the ES for C and EA of O (ESCEO) and the C of SA and NS of the IOF (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3–44. https://​doi.​org/​10.​1007/​s00198-018-4704-5CrossRef
11.
Zurück zum Zitat Amiche MA, Lévesque LE, Gomes T, Adachi JD, Cadarette SM (2018) Effectiveness of oral bisphosphonates in reducing fracture risk among oral glucocorticoid users: three matched cohort analyses. J bone Miner Res Off J Am Soc Bone Miner Res 33(3):419–429CrossRef Amiche MA, Lévesque LE, Gomes T, Adachi JD, Cadarette SM (2018) Effectiveness of oral bisphosphonates in reducing fracture risk among oral glucocorticoid users: three matched cohort analyses. J bone Miner Res Off J Am Soc Bone Miner Res 33(3):419–429CrossRef
12.
Zurück zum Zitat Majumdar SR, Lix LM, Morin SN, Yogendran M, Metge CJ, Leslie WD (2013) The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study. J Rheumatol 40(10):1736–1741CrossRef Majumdar SR, Lix LM, Morin SN, Yogendran M, Metge CJ, Leslie WD (2013) The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study. J Rheumatol 40(10):1736–1741CrossRef
13.
Zurück zum Zitat Trijau S, de Lamotte G, Pradel V, Natali F, Allaria-Lapierre V, Coudert H et al (2016) Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database. RMD open 2(2):e000249CrossRef Trijau S, de Lamotte G, Pradel V, Natali F, Allaria-Lapierre V, Coudert H et al (2016) Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database. RMD open 2(2):e000249CrossRef
14.
Zurück zum Zitat Feldstein AC, Elmer PJ, Nichols GA, Herson M (2005) Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 16(12):2168–2174CrossRef Feldstein AC, Elmer PJ, Nichols GA, Herson M (2005) Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 16(12):2168–2174CrossRef
15.
Zurück zum Zitat Koller G, Katz S, Charrois TL, Ye C (2019) Glucocorticoid-induced osteoporosis preventive care in rheumatology patients. Arch Osteoporos 14(1):16CrossRef Koller G, Katz S, Charrois TL, Ye C (2019) Glucocorticoid-induced osteoporosis preventive care in rheumatology patients. Arch Osteoporos 14(1):16CrossRef
16.
Zurück zum Zitat Compston J (2018) Glucocorticoid-induced osteoporosis: an update. Endocrine 61(1):7–16CrossRef Compston J (2018) Glucocorticoid-induced osteoporosis: an update. Endocrine 61(1):7–16CrossRef
17.
Zurück zum Zitat Silverman S, Curtis J, Saag K, Flahive J, Adachi J, Anderson F et al (2015) International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int 26:419–20CrossRef Silverman S, Curtis J, Saag K, Flahive J, Adachi J, Anderson F et al (2015) International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int 26:419–20CrossRef
18.
Zurück zum Zitat Kanis JA, McCloskey EV, Johansson H, Oden A, Ström O, Borgström F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21(Suppl 2):S407–S413CrossRef Kanis JA, McCloskey EV, Johansson H, Oden A, Ström O, Borgström F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21(Suppl 2):S407–S413CrossRef
20.
Zurück zum Zitat Leslie WD, Berger C, Langsetmo L, Lix LM, Adachi JD, Hanley DA et al (2011) Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int 22(6):1873–1883CrossRef Leslie WD, Berger C, Langsetmo L, Lix LM, Adachi JD, Hanley DA et al (2011) Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int 22(6):1873–1883CrossRef
21.
Zurück zum Zitat Overman RA, Yeh J-Y, Deal CL (2013) Prevalence of oral glucocorticoid usage in the United States: a general perspective. Arthritis Care Res 65(2):294–298CrossRef Overman RA, Yeh J-Y, Deal CL (2013) Prevalence of oral glucocorticoid usage in the United States: a general perspective. Arthritis Care Res 65(2):294–298CrossRef
24.
26.
Zurück zum Zitat Duru N, van der Goes MC, Jacobs JWG, Andrews T, Boers M, Buttgereit F, et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 72(12):1905 LP – 1913. Available from: http://ard.bmj.com/content/72/12/1905.abstract Duru N, van der Goes MC, Jacobs JWG, Andrews T, Boers M, Buttgereit F, et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 72(12):1905 LP – 1913. Available from: http://​ard.​bmj.​com/​content/​72/​12/​1905.​abstract
Metadaten
Titel
Evaluation of care delivery by a novel multidisciplinary bone health clinic for patients at risk of glucocorticoid-induced osteoporosis
verfasst von
Hasan Abdullah
Greg Koller
Ines Zuna
Nese Yuksel
Theresa Charrois
Rashmi Mandhane
Kathy Cotton
Melanie Danilak
Holly Bell
Carrie Ye
Publikationsdatum
01.12.2021
Verlag
Springer London
Erschienen in
Archives of Osteoporosis / Ausgabe 1/2021
Print ISSN: 1862-3522
Elektronische ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-021-00979-6

Weitere Artikel der Ausgabe 1/2021

Archives of Osteoporosis 1/2021 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.